A Phase Ib Open-label, Multicenter Cross-over Study to Investigate the Effect of Food on the Rate and Extent of Oral LBH589 Absorption in Patients With Advanced Solid Tumors
Interventional
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Levels of LBH589 in the blood
every week for the first 3 weeks
No
Novartis
Study Chair
Novartis
Sweden: Regional Ethical Review Board
CLBH589B2111
NCT00570284
November 2007
February 2011
Name | Location |
---|---|
Novartis Investigative Site | Boston, Massachusetts 02115 |
Novartis Investigative Site | Sacramento, California 95817 |
Novartis Investigative Site | Lebanon, New Hampshire 03756 |
Novartis Investigative Site | Buffalo, New York 14263 |
Novartis Investigative Site | Madison, Wisconsin 53792 |
Novartis Investigative Site | Baltimore, Maryland 21201 |
Novartis Investigative Site | Norwalk, Connecticut 06856 |